Do analysts recommend HVO or VRP?

hVIVO presently has a consensus target price of GBX 15, suggesting a potential upside of 70.16%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts clearly believe hVIVO is more favorable than Verona Pharma plc (VRP.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Verona Pharma plc (VRP.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, BTG or HVO?

hVIVO has lower revenue, but higher earnings than BTG. hVIVO is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BTG £159.40M 1.28 N/A £6.00 21.17 hVIVO £46.77M 1.30 £17.84M -£0.87 N/A

Is BTG or HVO more profitable?

BTG has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. BTG's return on equity of 0.00% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets BTG N/A N/A N/A hVIVO -12.48% -14.65% 11.97%

Does the media favor BTG or HVO?

In the previous week, BTG had 4 more articles in the media than hVIVO. MarketBeat recorded 5 mentions for BTG and 1 mentions for hVIVO. hVIVO's average media sentiment score of 0.78 beat BTG's score of 0.03 indicating that hVIVO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BTG 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral hVIVO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ARIX or HVO?

hVIVO has a consensus target price of GBX 15, suggesting a potential upside of 70.16%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has preferable valuation & earnings, ARIX or HVO?

hVIVO has higher revenue and earnings than Arix Bioscience. hVIVO is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arix Bioscience £14.16M 0.00 £14.96M £0.11 N/A hVIVO £46.77M 1.30 £17.84M -£0.87 N/A

Is ARIX or HVO more profitable?

Arix Bioscience has a net margin of 105.64% compared to hVIVO's net margin of -12.48%. Arix Bioscience's return on equity of 6.41% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets Arix Bioscience 105.64% 6.41% 2.18% hVIVO -12.48% -14.65% 11.97%

Do analysts rate HVO or CIR?

hVIVO currently has a consensus price target of GBX 15, suggesting a potential upside of 70.16%. Given hVIVO's stronger consensus rating and higher possible upside, research analysts plainly believe hVIVO is more favorable than Circassia Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Circassia Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer TILS or HVO?

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 70.16%. Given hVIVO's stronger consensus rating and higher probable upside, analysts clearly believe hVIVO is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

hVIVO (HVO) Competitors

GBX 8.82 +0.42 (+4.94%)

As of 12:25 PM Eastern

Compare

HVO vs. VRP, BTG, ARIX, CIR, and TILS

Should you buy hVIVO stock or one of its competitors? MarketBeat compares hVIVO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with hVIVO include Verona Pharma plc (VRP.L) (VRP), BTG (BTG), Arix Bioscience (ARIX), Circassia Group (CIR), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.

How does hVIVO compare to Verona Pharma plc (VRP.L)?

hVIVO (LON:HVO) and Verona Pharma plc (VRP.L) (LON:VRP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

hVIVO presently has a consensus target price of GBX 15, suggesting a potential upside of 70.16%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts clearly believe hVIVO is more favorable than Verona Pharma plc (VRP.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Verona Pharma plc (VRP.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

10.2% of hVIVO shares are held by institutional investors. 5.2% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, hVIVO had 1 more articles in the media than Verona Pharma plc (VRP.L). MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Verona Pharma plc (VRP.L). hVIVO's average media sentiment score of 0.78 beat Verona Pharma plc (VRP.L)'s score of 0.00 indicating that hVIVO is being referred to more favorably in the media.

Company	Overall Sentiment
hVIVO	Positive
Verona Pharma plc (VRP.L)	Neutral

Verona Pharma plc (VRP.L) has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Verona Pharma plc (VRP.L)'s return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Verona Pharma plc (VRP.L)	N/A	N/A	N/A

hVIVO has higher revenue and earnings than Verona Pharma plc (VRP.L). hVIVO is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.30	£17.84M	-£0.87	N/A
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A

Summary

hVIVO beats Verona Pharma plc (VRP.L) on 10 of the 13 factors compared between the two stocks.

How does hVIVO compare to BTG?

BTG (LON:BTG) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

BTG pays an annual dividend of GBX 4.30 per share and has a dividend yield of 3.4%. hVIVO pays an annual dividend of GBX 0.20 per share and has a dividend yield of 2.3%. BTG pays out 71.7% of its earnings in the form of a dividend. hVIVO pays out -23.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, BTG had 4 more articles in the media than hVIVO. MarketBeat recorded 5 mentions for BTG and 1 mentions for hVIVO. hVIVO's average media sentiment score of 0.78 beat BTG's score of 0.03 indicating that hVIVO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BTG	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
hVIVO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.7% of BTG shares are held by institutional investors. Comparatively, 10.2% of hVIVO shares are held by institutional investors. 19.7% of BTG shares are held by company insiders. Comparatively, 5.2% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BTG has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. BTG's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BTG	N/A	N/A	N/A
hVIVO	-12.48%	-14.65%	11.97%

hVIVO has lower revenue, but higher earnings than BTG. hVIVO is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BTG	£159.40M	1.28	N/A	£6.00	21.17
hVIVO	£46.77M	1.30	£17.84M	-£0.87	N/A

BTG presently has a consensus price target of GBX 160, suggesting a potential upside of 25.98%. hVIVO has a consensus price target of GBX 15, suggesting a potential upside of 70.16%. Given hVIVO's higher possible upside, analysts clearly believe hVIVO is more favorable than BTG.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

BTG beats hVIVO on 11 of the 16 factors compared between the two stocks.

How does hVIVO compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 10.2% of hVIVO shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by company insiders. Comparatively, 5.2% of hVIVO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

hVIVO has a consensus target price of GBX 15, suggesting a potential upside of 70.16%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

hVIVO has higher revenue and earnings than Arix Bioscience. hVIVO is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
hVIVO	£46.77M	1.30	£17.84M	-£0.87	N/A

In the previous week, hVIVO had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Arix Bioscience. hVIVO's average media sentiment score of 0.78 beat Arix Bioscience's score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.

Company	Overall Sentiment
Arix Bioscience	Neutral
hVIVO	Positive

Arix Bioscience has a net margin of 105.64% compared to hVIVO's net margin of -12.48%. Arix Bioscience's return on equity of 6.41% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
hVIVO	-12.48%	-14.65%	11.97%

Arix Bioscience has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, hVIVO has a beta of 1.685, indicating that its stock price is 69% more volatile than the broader market.

Summary

hVIVO beats Arix Bioscience on 9 of the 15 factors compared between the two stocks.

How does hVIVO compare to Circassia Group?

hVIVO (LON:HVO) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

hVIVO currently has a consensus price target of GBX 15, suggesting a potential upside of 70.16%. Given hVIVO's stronger consensus rating and higher possible upside, research analysts plainly believe hVIVO is more favorable than Circassia Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Circassia Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

10.2% of hVIVO shares are held by institutional investors. 5.2% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, hVIVO had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Circassia Group. hVIVO's average media sentiment score of 0.78 beat Circassia Group's score of 0.00 indicating that hVIVO is being referred to more favorably in the media.

Company	Overall Sentiment
hVIVO	Positive
Circassia Group	Neutral

Circassia Group has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Circassia Group's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Circassia Group	N/A	N/A	N/A

hVIVO has higher revenue and earnings than Circassia Group. hVIVO is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.30	£17.84M	-£0.87	N/A
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A

Summary

hVIVO beats Circassia Group on 9 of the 13 factors compared between the two stocks.

How does hVIVO compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 70.16%. Given hVIVO's stronger consensus rating and higher probable upside, analysts clearly believe hVIVO is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

hVIVO has higher revenue and earnings than Tiziana Life Sciences. hVIVO is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A
hVIVO	£46.77M	1.30	£17.84M	-£0.87	N/A

10.2% of hVIVO shares are owned by institutional investors. 5.2% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, hVIVO had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Tiziana Life Sciences. hVIVO's average media sentiment score of 0.78 beat Tiziana Life Sciences' score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.

Company	Overall Sentiment
Tiziana Life Sciences	Neutral
hVIVO	Positive

Tiziana Life Sciences has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Tiziana Life Sciences' return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
hVIVO	-12.48%	-14.65%	11.97%

Summary

hVIVO beats Tiziana Life Sciences on 10 of the 13 factors compared between the two stocks.

Get hVIVO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HVO vs. The Competition

Export

Metric	hVIVO	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£60.68M	£461.59M	£6.49B	£2.77B
Dividend Yield	2.68%	3.87%	2.67%	6.12%
P/E Ratio	-10.13	3.14	20.30	365.54
Price / Sales	1.30	6,606.57	517.33	87,173.10
Price / Cash	4.94	13.13	42.35	27.85
Price / Book	1.59	83.47	9.73	7.68
Net Income	£17.84M	-£96.07M	£3.56B	£5.89B
7 Day Performance	8.83%	-1.70%	-3.19%	-0.55%
1 Month Performance	19.12%	0.74%	-0.11%	3.15%
1 Year Performance	-18.00%	70.06%	25.29%	73.57%

hVIVO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HVO hVIVO	2.484 of 5 stars	GBX 8.82 +4.9%	GBX 15 +70.2%	-19.2%	£60.68M	£46.77M	N/A	N/A	Positive News
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up
BTG BTG	4.1624 of 5 stars	GBX 125 -0.4%	GBX 160 +28.0%	N/A	£201.31M	£159.40M	20.83	4,690	News Coverage Analyst Forecast
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HVO) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

hVIVO (HVO) Competitors

HVO vs. VRP, BTG, ARIX, CIR, and TILS

How does hVIVO compare to Verona Pharma plc (VRP.L)?

Summary

How does hVIVO compare to BTG?

Summary

How does hVIVO compare to Arix Bioscience?

Summary

How does hVIVO compare to Circassia Group?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

hVIVO (HVO) Competitors

HVO vs. VRP, BTG, ARIX, CIR, and TILS

How does hVIVO compare to Verona Pharma plc (VRP.L)?

Do analysts recommend HVO or VRP?

Do insiders & institutionals hold more shares of HVO or VRP?

Does the media refer more to HVO or VRP?

Is HVO or VRP more profitable?

Which has preferable earnings and valuation, HVO or VRP?

Summary

How does hVIVO compare to BTG?

Is BTG or HVO a better dividend stock?

Does the media favor BTG or HVO?

Do institutionals & insiders hold more shares of BTG or HVO?

Is BTG or HVO more profitable?

Which has higher valuation and earnings, BTG or HVO?

Do analysts rate BTG or HVO?

Summary

How does hVIVO compare to Arix Bioscience?

Do institutionals & insiders hold more shares of ARIX or HVO?

Do analysts recommend ARIX or HVO?

Which has preferable valuation & earnings, ARIX or HVO?

Does the media favor ARIX or HVO?

Is ARIX or HVO more profitable?

Which has more risk & volatility, ARIX or HVO?

Summary

How does hVIVO compare to Circassia Group?

Do analysts rate HVO or CIR?

Do insiders & institutionals believe in HVO or CIR?

Does the media favor HVO or CIR?

Is HVO or CIR more profitable?

Which has better earnings & valuation, HVO or CIR?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Do analysts prefer TILS or HVO?

Which has preferable earnings & valuation, TILS or HVO?

Do institutionals and insiders believe in TILS or HVO?

Does the media favor TILS or HVO?

Is TILS or HVO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools